Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track OTLK with free AI briefings, catalyst countdowns, and dilution alerts.

OTLK · Outlook Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$11.2M Cash on Hand
2.3mo Cash Runway
15.5% Short Interest
$5.03 Analyst Target (4)
Follow OTLK by email Get an email when OTLK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about OTLK, unsubscribe in one click. Privacy

📣 What OTLK Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Bevacizumab
FDA approved Jul 2026 · Lytenava
Age-Related Macular Degeneration Phase 3 · NCT05112861 Active not recruiting

Also used in these trials (approved or third-party drugs, not OTLK's own candidates): Ranibizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

OTLK holds $11.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $14.4M/quarter from operations, an estimated runway of 2.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 70 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when OTLK files for a raise →

👥 Who Owns OTLK

Insiders 11.2% Other 5%+ holders 8.6% Institutions 41.8% Public and other holders 38.4%
HolderTypeShares% of sharesAs of
GMS Ventures & Investments Institution (13G, 5%+) 42,631,142 17.51% 2026-08-12
Ghiath M. Sukhtian
Director, 10% owner · +21.47M options
Insider 24,617,320 10.11% 2026-08-12
Empery Asset Management, LP Institution (13G, 5%+) 21,247,856 8.73% 2026-09-30
CVI Investments, Inc. 5%+ holder (13G) 21,000,000 8.63% 2026-09-30
Vanguard Capital Management LLC Institution (13F) 8,976,833 3.69% 2026-09-30
Marshall Wace LLP Institution (13F) 8,023,703 3.30% 2026-09-30
Ameriprise Financial, Inc. Institution (13F) 5,050,505 2.07% 2026-09-30
UBS Group AG Institution (13F) 3,343,234 1.37% 2026-09-30
Perceptive Advisors Llc Institution (13F) 3,139,216 1.29% 2026-09-30
Geode Capital Management, LLC Institution (13F) 1,716,408 0.71% 2026-09-30
Syntone Ventures LLC
10% owner · +1.07M options
Insider 1,705,438 0.70% 2024-04-15
Blackrock Inc. Institution (13F) 1,667,775 0.69% 2026-09-30

Share count 243,447,554 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the largest 13F holders (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-09-01
filed 2026-09-02
Lundquist Kevin Michael
Option award (A) 500,000 – –
2026-08-14
filed 2026-08-14
Jahr Robert Charles
Purchase (P) 151,515 – –
2026-08-14
filed 2026-08-14
KENYON LAWRENCE A
Purchase (P) 101,010 – –
2026-08-14
filed 2026-08-14
KENYON LAWRENCE A
Purchase (P) 101,010 – 106,956
2026-08-12
filed 2026-08-14
Sukhtian Ghiath M.
Purchase (P) 2,525,252 – –

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-07-29 LYTENAVA BLA -47.1% +10.6% —
2025-12-31 ONS-5010/LYTENAVA NDA +4.2% -15.3% -68.4%

Browse all historical PDUFA outcomes →

Get the full OTLK picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for OTLK and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.